Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Consulting agrmnt
Appointed COO

Immune Therapeutics, Inc. (IMUN) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/20/2023 8-K Quarterly results
03/06/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
01/03/2023 8-K Quarterly results
11/09/2022 8-K Quarterly results
10/12/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "DEFINITIVE AGREEMENT INTELLECTUAL PROPERTY LICENSE AGREEMENT"
09/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors ORLANDO, FL, Sept. 27, 2022 — Immune Therapeutics, Inc . , a specialty pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products with a well-defined path to market, today announced the appointment of Louis Salomonsky to the Company’ s Board of Directors. “On behalf of the Board and leadership of Immune, I would like to welcome Louis to Immune’ s Board,” said Dr. Stephen Wilson, CEO of Immune. “Mr. Salomonsky’ s operational leadership, as well as his track record of deal-making and financial acumen, will be instrumental in moving our programs forward.” Commenting on his appointment, Mr. Salomonsky said, “I am excited to join Immune’ s Board to ..."
08/04/2022 8-K Quarterly results
07/22/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
06/02/2021 8-K Quarterly results
01/26/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/22/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Immune Therapeutics, Inc. Announces Signing of Definitive Merger Agreement Between Cytocom and Cleveland BioLabs Merger to create a single public company focused on the development and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions"
08/17/2020 8-K Quarterly results
07/27/2020 8-K Quarterly results
05/14/2020 8-K Other Events
05/05/2020 8-K Quarterly results
04/16/2020 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "SEC Extension application",
"Immune Therapeutics, Inc. and Forte Biotechnology Intl Corp Sign Sub-Licensing Agreement for Animal Health Applications"
03/20/2020 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Letter of Intent",
"Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19 By Corporate News, News, Press Releases Immune Therapeutics, Inc. Signs Binding Letter of Intent to Collaborate with Cytocom, Inc. to Develop"
02/19/2020 8-K Quarterly results
10/31/2019 8-K Quarterly results
09/25/2019 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Employment Agreement with Michael Handley"
07/01/2019 8-K Submission of Matters to a Vote of Security Holders
01/08/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/11/2018 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...
Docs: "Restated Agreement",
"Stock Agreement",
"Immune Therapeutics Acquires 10% Stake in Cytocom; Obtains Exclusive Rights to Lodonal™ for Pets in United States"
05/22/2018 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement
04/27/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Immune Therapeutics, Inc. Files New Drug Application for Lodonol™ in Kenya to Target HIV Epidemic Press Release | 04/26/2018"
03/28/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Immune Therapeutics, Inc. Received Minutes From FDA Meeting for Lodonal™ for the Treatment for Crohn’ s Disease"
12/29/2017 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/01/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Letter to Shareholders"
11/02/2017 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
09/08/2017 8-K Quarterly results
08/25/2017 8-K Quarterly results
06/09/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy